Latest news from BioDelivery Sciences International Inc. on News en-us Copyright 2024 News 115 31 / /images/newswise-logo-rss.gif /articles/expert-in-wake-of-obama-s-heroin-initiative-new-treatment-options-are-needed/?sc=rsin /articles/expert-in-wake-of-obama-s-heroin-initiative-new-treatment-options-are-needed/?sc=rsin Thu, 27 Aug 2015 08:45:00 EST Expert can discuss the need to address the issue of heroin and prescription opioid abuse by developing innovative medical treatments. Specifically, he can describe the features and benefits of an inside-the-cheek format of buprenorphine for the maintenance treatment of opioid addiction. BioDelivery Sciences International Inc. /articles/expert-state-of-opioid-abuse-spurs-search-for-new-options/?sc=rsin /articles/expert-state-of-opioid-abuse-spurs-search-for-new-options/?sc=rsin Tue, 26 May 2015 08:45:00 EST Expert can speak on the need for treatment of pain with less potential for abuse than existing painkillers; for better options for those already dealing with opioid dependence; and for the need to address patients' lifestyles as well as bodies to ensure optimal treatment. Dr. Mark Sirgo is president and CEO of BioDelivery Sciences, whose FDA-approved drug BUNAVAIL and investigational drug BELBUCA allow for the efficient delivery of buprenorphine while potentially overcoming some of the administration challenges presented by sublingual dosage forms, and whose Inreach Assist website and app offers a comprehensive array of information and resources to support patients dealing with addiction and their families. BioDelivery Sciences International Inc. /articles/pain-expert-discusses-new-drug-delivery-technology-and-safety-program-surrounding-novel-pain-treatment/?sc=rsin /articles/pain-expert-discusses-new-drug-delivery-technology-and-safety-program-surrounding-novel-pain-treatment/?sc=rsin Fri, 11 Sep 2009 13:00:00 EST In July 2009, the U.S. Food and Drug Administration approved ONSOLIS, also known as fentanyl buccal soluble film, from North Carolina-based BioDelivery Sciences International, Inc. (BDSI), for the management of breakthrough pain in patients with cancer, 18 years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. This opioid analgesic is anticipated to be available in the October of 2009 and will be commercialized in the U.S. by Meda Pharmaceuticals, the U.S. subsidiary of Meda AB. BioDelivery Sciences International Inc.